Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 125-129

  Liu, Zhikun ^a,b   Ling, Qi ^a,b   Wang, Jianguo ^a,b   Xie, Haiyang ^a,b   Xu, Xiao ^a,b   Zheng, Shusen ^a,b  

^a BEIJING HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Annexin A2; Hepatocellular carcinoma; Liver cirrhosis; Liver transplantation; Prognosis

Indexed keywords

LIPOCORTIN 2;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

EID: 84878294843     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1337     Document Type: Article

References (24)

1. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
2. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12: 1175-1181, 2006.
3. Inagaki Y, Xu HL, Hasegawa K, et al: Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J Dig Dis 12: 481-488, 2011.
4. Liu J and Fan D: Hepatitis B in China. Lancet 369: 1582-1583, 2007.
5. Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5 Suppl 1): S35-S50, 2004.
6. Fritz K, Fritz G, Windschiegl B, Steinem C and Nickel B: Arrangement of Annexin A2 tetramer and its impact on the structure and diffusivity of supported lipid bilayers. Soft Matter 6: 4084-4094, 2010.
7. Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 1477: 215-230, 2000.
8. Chiang Y, Rizzino A, Sibenaller ZA, Wold MS and Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem 199: 139-147, 1999.
9. Jacovina AT, Deora AB, Ling Q, et al: Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 119: 3384-3394, 2009.
10. Hajjar KA and Acharya SS: Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci 902: 265-271, 2000.
11. Takahashi S, Reddy SV, Chirgwin JM, et al: Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem 269: 28696-28701, 1994.
12. Huang Y, Jin Y, Yan CH, et al: Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 309: 117-123, 2008.
13. Bao H, Jiang M, Zhu M, Sheng F, Ruan J and Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90: 177-185, 2009.
14. Sarkar S, Swiercz R, Kantara C, Hajjar KA and Singh P: Annexin A2 mediates up-regulation of NF-κB, β-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology 140: 583-595: e583-e595, 2011.
15. Ji NY, Park MY, Kang YH, et al: Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med 24: 765-771, 2009.
16. Zhang L, Peng X, Zhang Z, et al: Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem 110: 219-228, 2010.
17. Lu AW, Zheng SS, Wu MP, Shen Y and Yang RW: Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 7: 357-361, 2008.
18. Zheng SS, Xu X, Wu J, et al: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85: 1726-1732, 2008.
19. Sun YL, Yin SY, Xie HY, et al: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol 23: 1280-1286, 2008.
20. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987 (In German).
21. Ozkan G, Tutar M, Bayram M, et al: The impact of ultrasonography-guided fine needle aspiration of no palpable supraclavicular lymph nodes on diagnosis and staging in advanced lung cancer. Tuberk Toraks 57: 186-191, 2009.
22. Zhang L, Jia X, Feng Y, et al: Plasma membrane proteome analysis of the early effect of alcohol on liver: implications for alcoholic liver disease. Acta Biochim Biophys Sin (Shanghai) 43: 19-29, 2011.
23. Seth D, Hogg PJ, Gorrell MD, McCaughan GW and Haber PS: Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease. J Hepatol 48: 614-627, 2008.
24. Jia XF, Peng X, Feng YL, Yang H, Yuan ZH and Zhang LJ: Subcellular proteome analysis of immune or alcohol induced rat liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 18: 826-830, 2010 (In Chinese).